Sichenzia Ross Ference LLP Represents Wize Pharma, Inc. in a $4.45 Million Private Placement
New York, NY – October 24, 2018 – Sichenzia Ross Ference LLP, announced today that it represented Wize Pharma, Inc. (OTCQB: “WIZP”), a clinical stage Israel based U.S. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common stock at $1.00 per share and 1,350 shares of newly created Series A preferred stock which is convertible at $1.00 per share.
The investors also received 100% 5 year Series A and 100% 6 month Series B warrants exercisable at $1.00 per share and $1.10 per share respectively. Wize received gross proceeds of $4.45 million.
The Sichenzia Ross Ference LLP team was led by Partner Gregory Sichenzia and Counsel Jeff Cahlon.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) in Offering of $1.2 Million American Depositary Shares - May 24, 2019
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8.0 Million Public Offering of Common Stock of Medalist Diversified REIT, Inc. - May 14, 2019
- Founding Partner Gregory Sichenzia to Moderate Cannabis Investor Panel - May 10, 2019